GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it will be available as the cover article in the upcoming July printed issue.

Read the full press release.